Newron Pharmaceuticals S.p.A.
NWPHF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $171,196 | $165,186 | $114,625 | $101,728 |
| - Cash | $6,933 | $7,897 | $6,338 | $7,713 |
| + Debt | $50,469 | $48,851 | $48,415 | $47,072 |
| Enterprise Value | $214,732 | $206,140 | $156,702 | $141,087 |
| Revenue | $47,983 | $3,407 | $3,563 | $5,494 |
| % Growth | 1,308.4% | -4.4% | -35.1% | – |
| Gross Profit | $47,983 | $3,407 | $3,563 | $5,494 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | $33,526 | -$7,587 | -$7,288 | -$4,204 |
| % Margin | 69.9% | -222.7% | -204.5% | -76.5% |
| Net Income | $25,400 | -$9,557 | -$9,274 | -$6,950 |
| % Margin | 52.9% | -280.5% | -260.3% | -126.5% |
| EPS Diluted | 1.36 | -0.51 | -0.52 | -0.39 |
| % Growth | 366.7% | 1.9% | -33.3% | – |
| Operating Cash Flow | -$8,786 | -$8,828 | -$4,537 | -$5,603 |
| Capital Expenditures | -$6 | -$7 | -$3 | -$8 |
| Free Cash Flow | -$8,792 | -$8,835 | -$4,540 | -$5,611 |